Pipeline dossier

NIH & clinical-trial pipeline signals for BeOne Medicines Ltd. (ONC)

Leading indicators across the NIH grant → clinical trial → SEC filing chain for ONC, mapped to public ticker ONC (CIK 0001651308). Sourced live from public data.

⚠ Research/informational signals from public data (NIH · ClinicalTrials.gov · SEC EDGAR). Not investment advice. Full scope →

Trial → FilingONC55% conf

BeOne Medicines Ltd. (ONC) — PHASE2 primary completion in ~133 days

Upstream (observed)
Clinical trial status (PHASE2) — A Dose-Escalation and Expansion Study of BGB-16673 in Participants With B-Cell Malignancies

↓ Phase-transition base rate 28% (Wong/Siah/Lo 2019)

Predicted downstream
SEC 8-K / press release on Phase 3 initiation (18-36 mo, base rate 28%)

trial ↗filings ↗

Recent SEC 8-K filings

2026-06-11 — 8-K 5.02,5.07,9.01 view ↗
2026-05-15 — 8-K 8.01,9.01 view ↗
2026-05-06 — 8-K 2.02,9.01 view ↗
2026-04-14 — 8-K 2.02,9.01 view ↗
2026-02-26 — 8-K 2.02,9.01 view ↗

JSON API for this entity →